Cancer Family
Central Nervous System Neoplasm
CI-CAN-00000118Explore in graph →
Non-malignant1,345 active trials7 approved drugs177 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000118Explore in graph →
Clinical trials
5,060 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05084092 | IORT After Surgical Resection of Brain Metastases(IORT_BRAINM1) | unknown | Phase 2 | 40 | Institut Català d'OncologiaOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05117814 | Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma | unknown | N/A | 20 | Peking University People's HospitalOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05477316 | A Study to Assess the Efficacy of Cerebellar IMRT Combined With Cerebral SRS in Patients With Brain Metastases | unknown | N/A | 37 | Hadassah Medical OrganizationOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05459441 | Efficacy and Safety Evaluation of Percutaneous Ommaya Capsule Injection of Autologous Bi-dimensional Specific T Cells in the Treatment of Glioma and in Combination With Pemetrexed in the Treatment of Brain/Meningeal Metastases | unknown | Early Phase 1 | 30 | Shanghai Pudong HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05447195 | Phase 2 Study of CAN008 in Subjects With GBM | unknown | Phase 2 | 117 | CANbridge Life Sciences Ltd.INDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT04845139 | A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma | unknown | N/A | 1 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT05099068 | Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET)(PLANET) | unknown | N/A | 500 | Centre Leon BerardOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT03286023 | Stereotactic Radiotherapy for Brain Metastases(CKBrainMeta) | unknown | — | 110 | Centre Francois Baclesse, LuxembourgOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05425654 | RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL | unknown | Phase 2 | 30 | National Research Center for Hematology, RussiaNETWORK | 1 | Jun 21, 2022 | clinicaltrials |
| NCT03243461 | International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)(HIT-HGG-2013) | unknown | Phase 3 | 167 | University of GöttingenOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT03226483 | Intraoperative Radiotherapy After the Resection of Brain Metastases(INTRAMET) | unknown | N/A | 50 | Universitätsmedizin MannheimOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT04831658 | A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Mingzhi ZhangOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05028270 | Treatment of Intraocular Retinoblastoma | unknown | — | 1,600 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jun 1, 2022 | clinicaltrials |
| NCT05399524 | Functional and Ultrasound Guided Resection of Glioblastoma(FUTURE-GB) | unknown | N/A | 357 | University of OxfordOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05398224 | R-MTX-zanbrutinib in Secondary CNS Lymphoma | unknown | Phase 2 | 45 | Peking UniversityOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT04501731 | Controlling Coordination After Childhood Cerebellar Cancer, a Pilot Study(5C-pilot) | unknown | — | 10 | University of NottinghamOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT05390749 | Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL | unknown | Phase 2 | 50 | Peking Union Medical College HospitalOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT05385185 | Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer | unknown | Phase 2 | 20 | Hebei Medical UniversityOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT00045968 | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer(GBM) | unknown | Phase 3 | 348 | Northwest BiotherapeuticsINDUSTRY | 4 | May 18, 2022 | clinicaltrials |
| NCT05366062 | ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab | unknown | Phase 2 | 28 | Epitopoietic Research CorporationINDUSTRY | 1 | May 13, 2022 | clinicaltrials |
| NCT02623010 | Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma | unknown | Phase 2 | 30 | Rabin Medical CenterOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT00075387 | Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors | unknown | Phase 2 | 48 | OHSU Knight Cancer InstituteOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT05333588 | The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme. | unknown | Early Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05334238 | Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma | unknown | Phase 3 | 174 | Ruijin HospitalOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02973256 | Oncological Care for Patients With Meningioma(ATYPICMENING) | unknown | — | 1,204 | University Hospital, MontpellierOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT04514393 | Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma | unknown | Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT05051488 | Dynamic Decompressive Craniotomy | unknown | — | 20 | Rohit Khanna, MDINDUSTRY | 0 | Apr 6, 2022 | clinicaltrials |
| NCT05308043 | Deep Learning in Retinoblastoma Detection and Monitoring. | unknown | — | 200 | Beijing Tongren HospitalOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT04738110 | Post-operative Imaging in High Grade Glioma: is Management Influenced?(PIGMI) | unknown | — | 150 | King's College Hospital NHS TrustOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05300113 | Artificial Intelligence Neuropathologist | unknown | — | 1,000 | Huashan HospitalOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT05287750 | Brain Diseases on 7.0T Magnetic Resonance Imaging | unknown | N/A | 200 | Chinese PLA General HospitalOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05202899 | Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy | unknown | Phase 4 | 40 | Guangzhou General Hospital of Guangzhou Military CommandOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT01951469 | Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer | unknown | Phase 3 | 160 | Sun Yat-sen UniversityOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT02313389 | Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma(BLOCAGE-01) | unknown | Phase 3 | 428 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04967027 | Phase 1 Trial for Tumor Treating Field for Drug/Radiation Resistant Brain Metastases | unknown | Early Phase 1 | 5 | Xiangya Hospital of Central South UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04253496 | Mathematic Modeling at Micro and Macroscopic Level of Primary Central Nervous System Lymphomas (PCNSL)(LOC-MODEL) | unknown | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT05177185 | Hippocampal-Sparing Stereotactic Radiosurgery Treatment of Brain Metastases Using CyberKnife(HiSparCK) | unknown | Phase 2 | 70 | Ottawa Hospital Research InstituteOTHER | 0 | Feb 16, 2022 | clinicaltrials |
| NCT05207904 | Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases | unknown | Phase 2 | 41 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT04539431 | Glioma Brain Tumours - E12513 - SensiScreen Glioma | unknown | — | 220 | Ente Ospedaliero Cantonale, BellinzonaOTHER | 1 | Jan 24, 2022 | clinicaltrials |
| NCT02796261 | Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients(STELLAR) | unknown | Phase 3 | 343 | Orbus Therapeutics, Inc.INDUSTRY | 8 | Jan 21, 2022 | clinicaltrials |
| NCT05201326 | Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma | unknown | Phase 1 | 20 | Ruijin HospitalOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT05199363 | Pediatric Patient Experience on a Diagnostic Path | unknown | N/A | 300 | Children's Memorial Health Institute, PolandOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT05188534 | ZOOMit-fMRI Identifies Language Functional Cortex | unknown | — | 60 | Beijing Neurosurgical InstituteOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT05143775 | Strategic Intervention on Preserving Language Function During Awake Craniotomy | unknown | N/A | 60 | Beijing Neurosurgical InstituteOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05167630 | Prognosis Factors in Patients With Primary Central Nervous System Lymphoma | unknown | — | 40 | Zhengzhou UniversityOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT05143788 | Strategic Intervention on Preserving Motor Function During Awake Craniotomy | unknown | N/A | 60 | Beijing Neurosurgical InstituteOTHER | 0 | Dec 20, 2021 | clinicaltrials |
| NCT03400917 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma | unknown | Phase 2 | 55 | Aivita Biomedical, Inc.INDUSTRY | 1 | Dec 16, 2021 | clinicaltrials |
| NCT05160818 | Hypofractionated Versus Single Fraction Stereotactic Adjuvant Radiotherapy to the Resection Cavity of Brain Metastases(SATURNUS) | unknown | N/A | 126 | Technical University of MunichOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT04888611 | Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma | unknown | Phase 2 | 40 | Huashan HospitalOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT05131711 | Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG)(CSREIG) | unknown | Phase 1 / Phase 2 | 60 | Beijing Tiantan HospitalOTHER | 1 | Nov 23, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Aug 4, 2022source: clinicaltrials